Transaction #13852 · Form 4 · 0001123292-25-000675
Xilio Therapeutics, Inc. · Other acquisition · Prefunded Warrants (right to buy)
Xilio Therapeutics, Inc. · Transacted November 26, 2025 · Filed December 1, 2025
What does this filing report?
An SEC Form 4 filing for Xilio Therapeutics, Inc. records an other acquisition involving Prefunded Warrants (right to buy) on November 26, 2025. The reported quantity was 13,335,000. The filing date is December 1, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Xilio Therapeutics, Inc.
- Company CIK
- 0001840233
- Security type
- Derivative
- Acquisition type
- Other acquisition · Code X
- Quantity acquired
- 13,335,000
- Reported price
- 0.7499 · See footnotes
- Reference value
- 9,999,916.5
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 36,645,266
- Ownership description
- Not reported
- SEC acceptance time
- Dec 1, 2025, 4:36 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- GILEAD SCIENCES, INC. ↗
10% owner
CIK 0000882095
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 13,335,000
- Conversion / exercise price
- 0.0001
- Exercise date
- Not reported
- Expiration date
- Not reported
Filing footnotes & remarks
- F1
- The Reporting Person acquired 13,335,000 Prefunded Warrants upon the exercise of an equal number of Series B Warrants at an exercise price of $0.7499 per warrant. A holder of either such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the "Common Stock").
- F2
- The Prefunded Warrants are exercisable at any time on or after the date of issuance and have no expiration date.
- F3
- The exercise price of the Series B Warrants was $0.75 per share of Common Stock. Because the Reporting Person chose to receive Prefunded Warrants in lieu of Common Stock upon exercise of the Series B Warrants, the exercise price was $0.75 less $0.0001 per share.
- F4
- The Series B Warrants were exercisable at any time on or after November 1, 2025 and would have expired on December 2, 2025, provided that if the closing price of the Common Stock was below the exercise price on such date, the exercise price would have reset to the closing price on December 1, 2025 and the expiration time would have been extended to December 31, 2025.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.